A confirmation of CBFB rearrangement and consequently the diagnosis of inv(16)/t(16;16) AML are decisive for the clinical management of the patients, e.g., whether to administer cytarabine-based intensive chemotherapy and the likelihood of a favorable response [3,28,29,30]. Here, CBFB is linked to acute myeloid leukemia.